Search results for "FDG PET"

showing 10 items of 14 documents

Utilidad del análisis de los parámetros metabólicos de la 18F-FDG PET/TC en pacientes con cáncer de mama. Valor añadido de la tomografía por emisión …

2019

UTILIDAD DEL ANÁLISIS DE LOS PARÁMETROS METABÓLICOS DE LA 18F-FDG PET-TC EN PACIENTES CON CÁNCER DE MAMA. VALOR AÑADIDO DE LA TOMOGRAFÍA POR EMISIÓN DE POSITRONES (MAMMI-PET) La hipótesis principal es que los parámetros metabólicos obtenidos de la 18F-FDG PET/TC (SUV máx, GTL y VMT) en pacientes con cáncer de mama podrían ser útiles en la valoración pronóstica dependiendo del perfil IHQ de los tumores. Objetivos secundarios: - Correlacionar parámetros metabólicos analizados con perfiles IHQ. - Correlacionar parámetros metabólicos con características clínico-tumorales (edad, tipo y grado histológico, localización y tamaño tumoral, actividad proliferativa ki67, expresión de receptores). - Cor…

18F-FDG PET/TCUNESCO::CIENCIAS MÉDICAS ::Patología::OncologíaUNESCO::CIENCIAS MÉDICAS:CIENCIAS MÉDICAS ::Patología::Oncología [UNESCO]:CIENCIAS MÉDICAS [UNESCO]cáncer de mamamammiPET
researchProduct

Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria

2016

BACKGROUND: In this paper the clinical value of PET for early prediction of tumor response to erlotinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen is evaluated. The aim was to compare the early metabolic treatment response using European Organization for Research and Treatment of Cancer (EORTC) 1999 recommendations and PET Response Criteria in Solid Tumors (PERCIST), and the standard treatment response using Response Evaluation Criteria in Solid Tumors (RECIST). METHODS: Twenty patients with stage IV NSCLCwere enrolled prospectively. PET/CT studies were performed before, then 48 hours, and 45 days after…

AdultMaleLung NeoplasmsTime FactorsAntineoplastic AgentsKaplan-Meier EstimateAdult; Aged; Antineoplastic Agents; Carcinoma Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prospective Studies; Time Factors; Treatment OutcomeResponse evaluation criteria in solid tumorDisease-Free SurvivalErlotinib Hydrochloridenon–small cell lung cancerPositron Emission Tomography Computed TomographyHumansProspective StudiesNon-Small-Cell LungAgedCarcinomaMiddle AgedCarcinoma non-small-cell lungEORTCTreatment OutcomeRECISTResponse evaluation criteria in solid tumorsFemalePositron-emission tomographyPERCISTDiagnosi18F-FDG PET
researchProduct

Factor analysis-based approach for early uptake automatic quantification of breast cancer by 18F-FDG PET images sequence

2014

International audience; Factor Analysis of Medical Image Sequences (FAMIS) is recognized as one pioneer successfully used approach for analyzing especially dynamic images' sequence for estimating kinetics and associated compartments having a physiological meaning. Some studies tried to extend the exploring of this approach to analyze Positron Emission Tomography (PET) image modality for dynamic sequences. PET images with 18F-fluorodesoxyglucose (18F-FDG) is the gold standard for in vivo, evaluation of tumor glucose metabolism and is widely used in clinical oncology. In this paper, a novel approach is proposed to obtain an automated quantification method for early accumulation of 18F-FDG tra…

Health InformaticsStandardized uptake value[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine030218 nuclear medicine & medical imaging18f fdg pet03 medical and health sciencessymbols.namesake0302 clinical medicineBreast cancermedicineComputingMilieux_MISCELLANEOUSSequencemedicine.diagnostic_testbusiness.industryCancerPattern recognitionGold standard (test)medicine.diseasePearson product-moment correlation coefficient3. Good healthPositron emission tomography030220 oncology & carcinogenesisSignal ProcessingsymbolsArtificial intelligencebusinessNuclear medicineBiomedical Signal Processing and Control
researchProduct

Development of a gene panel for 18F-FDG PET positivity prediction in gastric cancer.

2020

420 Background: 18F-FDG PET is widely used in clinical cancer diagnostics. However, 18F-FDG PET scan in gastric cancer (GC) is still controversial because of its lower sensitivity in diagnosis and staging compared to other imaging modalities. The purpose of this study was to establish a gene panel for 18F-FDG PET positivity in GC by using patient-derived xenografts (PDXs). Methods: BALB/c nude mice were subcutaneously implanted with 30 cases of GC PDX tissues and underwent a simultaneous PET/MRI scanner. Using RNA-seq data of the 30 GC PDXs for training set, we constructed a gene co-expression network which was correlated with the maximal standardized uptake values (SUVmax). The least abso…

OncologyCancer Researchmedicine.medical_specialtyOncologybusiness.industryInternal medicinemedicineCancermedicine.diseasebusinessGene18f fdg petJournal of Clinical Oncology
researchProduct

Impact of molecular and histological subtype of breast cancer on 18FDG-PET/CT imaging: Knowledge gained from recent studies

2016

International audience; Over the past few years, several studies have focused attention on the impact of breast cancer (BC) histological subtype or BC phenotype, as defined by hormone receptors (HR) and HER2 status, on the results of FDG-PET/CT at staging, or during neoadjuvant chemotherapy (NAC). At staging, sclerotic bone metastases from invasive lobular carcinoma (ILC) demonstrated low or no FDG uptake in comparison to metastases from invasive ductal carcinoma (IDC). The CT component of PET/CT imaging should be carefully analyzed in the staging of ILC. In patients with triple negative or HER2-positive tumors, the proportion of extraskeletal metastases is high; this must be taken into acc…

Oncologymedicine.medical_specialtyPathologyStagingPET/CTmedicine.medical_treatmentBiophysicsEstrogen receptorER-positive breast cancerNeoadjuvant chemotherapy030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineBreast cancerBreast cancerTriple-negative breast cancerResponse assessmentInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyMedicineRadiology Nuclear Medicine and imagingskin and connective tissue diseasesHER2-positive breast cancerTriple-negative breast cancerChemotherapyPET-CTPathological complete responseRadiological and Ultrasound Technologybusiness.industrymedicine.disease18fdg pet ctPrognosis3. Good healthHormone receptor030220 oncology & carcinogenesisInvasive lobular carcinoma(18)FDGbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Metabolic Response Assessment in Non-Small Cell Lung Cancer Patients after Platinum-Based Therapy: A Preliminary Analysis

2015

The purpose of this study was to evaluate the clinical value of PET (Positron Emission Tomography) for early prediction of tumor response to platinum-based therapy in patients with nonsmall cell lung cancer (NSCLC). The evaluation was carried out comparing the standard treatment response using RECIST (Response Evaluation Criteria in Solid Tumors) with metabolic treatment response according to European Organization for Research and Treatment of Cancer (EORTC) recommendations, PET Response Criteria in Solid Tumors (PERCIST), Total Lesion Glycolysis (TLG) and Metabolic Tumor Volume (MTV). Seventeen inoperable patients with stage IV NSCLC were enrolled between October 2011 and June 2013: PET st…

Oncologymedicine.medical_specialtybusiness.industryF-FDG PETmedicine.disease18 F-FDG PET EORTC Non-small cell lung cancer PERCIST RECIST Therapy MonitoringPreliminary analysisResponse assessmentEORTCNon-small cell lung cancerRECISTTherapy MonitoringInternal medicinemedicineF-18-FDG PETRadiology Nuclear Medicine and imagingTherapy monitoringRadiologyNon small cellLung cancerbusinessPERCIST
researchProduct

[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy

2007

To evaluate, in breast cancer patients treated by neoadjuvant chemotherapy, the predictive value of reduction in FDG uptake with regard to complete pathological response (pCR).Forty-seven women with non-metastatic, non-inflammatory, large or locally advanced breast cancer were included. Tumour uptake of FDG was evaluated before and after the first course of neoadjuvant chemotherapy. Four indices were used: maximal and average SUV without or with correction by body surface area and glycaemia (SUV(max), SUV(avg), SUV(max-BSA-G) and SUV(avg-BSA-G), respectively). The predictive value of reduction in FDG uptake with respect to pCR was studied by logistic regression analysis. Relationships betwe…

Oncologymedicine.medical_specialtymedicine.medical_treatmentPathological responseAntineoplastic AgentsBreast Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineSensitivity and Specificity030218 nuclear medicine & medical imaging18f fdg pet[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciences0302 clinical medicineBreast cancerFluorodeoxyglucose F18Internal medicinemedicineHumansRadiology Nuclear Medicine and imagingNeoadjuvant therapyComputingMilieux_MISCELLANEOUSChemotherapymedicine.diagnostic_testbusiness.industryFdg uptakeReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseasePrognosisNeoadjuvant Therapy3. Good healthClinical trialTreatment OutcomePositron emission tomography030220 oncology & carcinogenesisPositron-Emission TomographyFemaleRadiopharmaceuticalsbusiness
researchProduct

Analysis of Metabolic Parameters Coming from Basal and Interim PET in Hodgkin Lymphoma

2018

Objective: Positron Emission Tomography (PET) with F-18-Fluoro-deoxy-glucose (FDG) emerged as a prognostic tool to predict treatment outcome in Hodgkin Lymphoma (HL). Moreover, a FDG-PET adapted strategy is currently assessed in clinical trial to minimize the toxic effect while maintaining the efficacy of treatment in HL. Purpose was to analyze the quantitative parameters to support the prognostic role of FDG-PET today based on the semi-quantitative Deauville 5-point Scale (D5-PS). Methods: This retrospective study included 53 patients diagnosed with advanced-stage HL between 2009 and 2014, enrolled in the PET response-adapted clinical trial HD 0607. FDG-PET was performed at baseline (PET0)…

Pathologymedicine.medical_specialtyChemothrapy; FDG PET; Hodgkin lymphoma; Metabolic parameters; Metabolic tumor volume; Prognostic value; Radiology Nuclear Medicine and Imagingbusiness.industryHODGkin lymphomaMetabolic tumor volume02 engineering and technology021001 nanoscience & nanotechnologyInterim pet03 medical and health sciencesBasal (phylogenetics)0302 clinical medicineNuclear Medicine and ImagingFDG PETmedicineHodgkin lymphomaRadiology Nuclear Medicine and imaging030212 general & internal medicineMetabolic parametersRadiology0210 nano-technologyNuclear medicinebusinessPrognostic valueChemothrapyCurrent Medical Imaging Reviews
researchProduct

A xanthogranulomatous process resembling residual disease on endof- treatment 18f-FDG-PET/CT and Whole Body Magnetic Resonance performed on a primary…

2016

We report the case of a woman, affected by breast diffuse large B-Cell lymphoma, who developed a xanthogranulomatous process wrongly interpreted as residual disease on 18F-FDG-PET/CTand Whole Body Magnetic Resonance after treatment with ibrutinib plus standard immunochemotherapy. Newer drugs, such as immunomodulatory agents and checkpoint inhibitors, have demonstrated high effectiveness on lymphoma, but are associated with unclear imaging features such as tumor flare or pseudo-progression, related to inflammatory reactions. Wide imaging techniques availability improves diagnostic possibilities. However, the awareness of the adopted treatment strategy and its possible implications on imaging…

Pathologymedicine.medical_specialtyWhole body magnetic rcsonanccmedicine.diagnostic_testbusiness.industryIbrutinibObstetrics and GynecologyMagnetic resonance imagingCHOPFDG-PET/CTBrcasr lymphoma; FDG-PET/CT; Ibrutinib; Rituximab; Whole body magnetic rcsonancc; Xantogranulomatous process; Obstetrics and GynecologyPrimary Breast Lymphomachemistry.chemical_compoundchemistryXantogranulomatous proceIbrutinibmedicineFdg pet ctRituximabRituximabWhole bodybusinessNuclear medicineBrcasr lymphomamedicine.drugGiornale Italiano di ostetricia e ginecologia
researchProduct

Metabolic impact of Partial Volume Correction of [18F]FDG PET-CT oncological studies on the assessment of tumor response to treatment

2014

AIM: The aim of this work is to evaluate the metabolic impact of Partial Volume Correction (PVC) on the measurement of the Standard Uptake Value (SUV) from [18F]FDG PET-CT oncological studies for treatment monitoring purpose. METHODS: Twenty-nine breast cancer patients with bone lesions (42 lesions in total) underwent [18F]FDG PET-CT studies after surgical resection of breast cancer primitives, and before (PET-I) and after (PET-II) chemotherapy and hormone treatment. PVC of bone lesion uptake was performed on the two [18F]FDG PET-CT studies, using a method based on Recovery Coefficients (RC) and on an automatic measurement of lesion metabolic volume. Body-weight average SUV was calculated f…

Settore ING-INF/05 - Sistemi Di Elaborazione Delle InformazioniPhantoms ImagingReproducibility of ResultsAntineoplastic AgentsBone NeoplasmsBreast NeoplasmsMiddle AgedMultimodal ImagingBone and bonePositron-emission tomography Standardized uptake value Partial volume correction bone metastases therapy monitoringFluorodeoxyglucose F18[18F]FDG PET-CT oncologicalHumansRadiographic Image Interpretation Computer-AssistedFemaleNeoplasm MetastasisPositron-emission tomographyTomography X-Ray ComputedNeoplasm metastasiAged
researchProduct